AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Novartis AG ADR (NYSE:NVS)
153.76 USD
+1.030 0.674%Sponsored Reports
Loading...
| Previous Close (in USD) | 152.73 |
|---|---|
| Change | +1.030 0.674% |
| 52 W H/L (in USD) | 105.610/79.639 |
| EBITDA (in USD) | 21593M |
| PE Ratio | 25.58 |
| Volume | 2591831 |
| Diluted Eps TTM | 3.86 |
| Total Assets (in USD) | 117453M |
|---|---|
| Total Liabilities (in USD) | 58030M |
| Revenue TTM (in USD) | 54216.999M |
| Cash (in USD) | 7517M |
| Market Cap (in USD) | 202,976.674 M |
| Revenue Per Share TTM | 25.843 |
| Gross Profit TTM (in USD) | 36744M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Novartis AG ADR
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Employees: 101703
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Vasant Narasimhan | Chief Exec. Officer | 1976 |
| 2. | Mr. Harry Kirsch | Chief Financial Officer | 1965 |
| 3. | Dr. Klaus Moosmayer Ph.D. | Chief Ethics, Risk & Compliance Officer | 1968 |
| 4. | Ms. Karen L. Hale | Chief Legal Officer | 1968 |
| 5. | Dr. Robert Kowalski Pharm.D. | Chief People & Organization Officer | 1968 |
| 6. | Mr. Steffen Lang Ph.D. | Pres of Operations | 1967 |
| 7. | Ms. Marie-France Tschudin | Pres of Innovative Medicines International & Chief Commercial Officer | 1971 |
| 8. | Mr. Richard Saynor | Chief Exec. Officer of Sandoz | 1967 |
| 9. | Paul Penepent | Head of Group Financial Reporting and Accounting | NA |
| 10. | Dr. Samir Shah M.D. | Global Head of Investor Relations | NA |
Peers
Sector: Healthcare
Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
LLY
Eli Lilly and Company |
+9.940 0.850% | 1159.445 | 78.140 | 31.949 | 16.338 | 45.832 | 16.647 | 54.359 |
|
JNJ
Johnson & Johnson |
+3.070 1.228% | 252.59 | 29.170 | 14.327 | 3.740 | 5.180 | 3.805 | 15.225 |
|
ABBV
AbbVie Inc |
+0.100 0.039% | 257 | 86.320 | 14.327 | 5.891 | 50.457 | 7.044 | 24.438 |
|
AZN
AstraZeneca PLC |
-0.390 0.230% | 168.15 | 30.690 | 19.231 | 5.297 | 6.445 | 5.721 | 17.228 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | 8371M | 26137M | 9878M | 8940M | 13835M |
| Minority Interest | 0M | 3M | 68M | 77M | 78M |
| Net Income | 6955M | 24021M | 8072M | 7147M | 12611M |
| Selling General Administrative | 14253M | 14815M | 14197M | 14369M | 16471M |
| Gross Profit | 36342M | 37010M | 34777M | 34252M | 34759M |
| Reconciled Depreciation | 7181M | 6113M | 6464M | 5826M | 6892M |
| Ebit | 9197M | 26948M | 10152M | 9086M | 14858M |
| Ebitda | 16389M | 33061M | 17211M | 15616M | 21750M |
| Depreciation And Amortization | 7192M | 6113M | 7059M | 6530M | 6892M |
| Operating Income | 9197M | 26948M | 10152M | 9086M | 8169M |
| Other Operating Expenses | 42631M | 41188M | 39746M | 39591M | 44997M |
| Interest Expense | 837M | 811M | 869M | 850M | 957M |
| Tax Provision | 1416M | 2119M | 1807M | 1793M | 1295M |
| Interest Income | 379M | 14628M | 91M | 36M | 5M |
| Net Interest Income | -633M | -891M | -947M | -645M | -706M |
| Income Tax Expense | 1416M | 2119M | 1807M | 1793M | 1221M |
| Total Revenue | 51828M | 52877M | 49898M | 48677M | 53166M |
| Total Operating Expenses | 27145M | 25321M | 24625M | 25166M | 26590M |
| Cost Of Revenue | 15486M | 15867M | 15121M | 14425M | 18407M |
| Total Other Income Expense Net | -826M | -811M | -274M | -146M | 6372M |
| Net Income From Continuing Ops | 6955M | 24018M | 8071M | 7147M | 12614M |
| Net Income Applicable To Common Shares | 6955M | 24021M | 8072M | 11732M | 12611M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Total Assets | 117453M | 131795M | 132059M | 118370M | 145563M |
| Intangible Assets | 31644M | 34182M | 36809M | 28787M | 38719M |
| Other Current Assets | 2471M | 2440M | 2523M | 2680M | 1619M |
| Total Liab | 58030M | 63973M | 75393M | 62819M | 66871M |
| Total Stockholder Equity | 59342M | 67655M | 56598M | 55474M | 78614M |
| Other Current Liab | 17205M | 17962M | 17529M | 15449M | 14195M |
| Common Stock | 890M | 901M | 913M | 936M | 944M |
| Capital Stock | 890M | 901M | 913M | 936M | 944M |
| Retained Earnings | 63540M | 70989M | 57157M | 59275M | 82191M |
| Good Will | 29301M | 29595M | 29999M | 26524M | 35294M |
| Other Assets | 4849M | 12425M | 14728M | 14799M | 25549M |
| Cash | 7517M | 12407M | 9658M | 11112M | 13271M |
| Cash And Equivalents | 4640M | 9011M | 5908M | 7865M | 10150M |
| Total Current Liabilities | 28656M | 30208M | 33059M | 28264M | 29607M |
| Current Deferred Revenue | 123M | 123M | 56M | 114M | 236M |
| Net Debt | 20447M | 18686M | 28391M | 18221M | 18819M |
| Short Term Debt | 6182M | 6570M | 10071M | 7277M | 9620M |
| Short Long Term Debt | 5876M | 6227M | 9591M | 6846M | 9620M |
| Short Long Term Debt Total | 27964M | 31093M | 38049M | 29333M | 32090M |
| Other Stockholder Equity | -92M | -48M | -53M | -80M | -69M |
| Property Plant Equipment | 12195M | 13106M | 13939M | 13746M | 15696M |
| Total Current Assets | 36910M | 45718M | 29673M | 29504M | 35563M |
| Long Term Investments | 1606M | 2268M | 11700M | 11162M | 10697M |
| Short Term Investments | 11413M | 15922M | 1905M | 334M | 2693M |
| Net Receivables | 8334M | 8283M | 8456M | 8555M | 11024M |
| Long Term Debt | 20244M | 22902M | 26259M | 20353M | 22470M |
| Inventory | 7175M | 6666M | 7131M | 5982M | 6956M |
| Accounts Payable | 5146M | 5553M | 5403M | 5424M | 5556M |
| Accumulated Other Comprehensive Income | 58544M | 66802M | 55738M | 54618M | 77739M |
| Non Currrent Assets Other | 1110M | 2210M | 892M | 738M | 895M |
| Non Current Assets Total | 80543M | 86077M | 102386M | 88866M | 110000M |
| Capital Lease Obligations | 1789M | 1896M | 2005M | 1949M | - |
| Long Term Debt Total | 21782M | 24523M | 27978M | 22056M | 22470M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 1468M | 6815M | -13182M | -2226M | -5591M |
| Total Cashflows From Investing Activities | 1468M | 4208M | -13182M | -2226M | -5591M |
| Total Cash From Financing Activities | -20562M | -16264M | -2208M | -13627M | -4244M |
| Net Income | 6955M | 24018M | 8071M | 7147M | 12614M |
| Change In Cash | -4890M | 2749M | -1454M | -2159M | 4411M |
| Begin Period Cash Flow | 12407M | 9658M | 11112M | 13271M | 8860M |
| End Period Cash Flow | 7517M | 12407M | 9658M | 11112M | 13271M |
| Total Cash From Operating Activities | 14236M | 15071M | 13650M | 13625M | 14272M |
| Depreciation | 7181M | 6113M | 6464M | 5826M | 6892M |
| Other Cashflows From Investing Activities | 4139M | -57M | -186M | -1216M | -1031M |
| Dividends Paid | 7506M | 7368M | 6987M | 6645M | 6966M |
| Change To Inventory | -830M | 81M | -543M | -382M | -533M |
| Sale Purchase Of Stock | -10652M | -3057M | -2842M | -5533M | -2036M |
| Other Cashflows From Financing Activities | 466M | 94M | -149M | 50M | -113M |
| Capital Expenditures | 2671M | 2971M | 2585M | 2257M | 3355M |
| Change In Working Capital | -1003M | 241M | -291M | 199M | 499M |
| Other Non Cash Items | -1136M | -18156M | -3139M | -2098M | -7713M |
| Free Cash Flow | 11565M | 12100M | 11065M | 11368M | 10917M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Dodge & Cox Stock I | 2 years ago | 11800308 |
| 2. | Vanguard PRIMECAP Inv | 2 years ago | 8961185 |
| 3. | Vanguard Capital Opportunity Inv | 2 years ago | 2230990 |
| 4. | Franklin Mutual Global Discovery Z | 2 years ago | 2028207 |
| 5. | Hartford Dividend and Growth Y | 2 years ago | 2016519 |
| 6. | Principal Equity Income A | 2 years ago | 1851303 |
| 7. | DFA International Core Equity I | 2 years ago | 1622126 |
| 8. | Loomis Sayles Growth Y | 2 years ago | 1573542 |
| 9. | Franklin Mutual Shares Z | 2 years ago | 1558716 |
| 10. | Vanguard PRIMECAP Core Inv | 2 years ago | 1547300 |
| 11. | Russell CDN_Core Equity SMA | 2 years ago | 1417467 |
| 12. | Franklin Mutual Beacon Z | 2 years ago | 1128819 |
| 13. | Janus Henderson Global Life Sciences | 2 years ago | 1083587 |
| 14. | Janus Henderson Global Life Sciences D | 2 years ago | 1083587 |
| 15. | Dimensional International Value ETF | 2 years ago | 1040186 |
| 16. | Vanguard Windsor™ II Inv | 2 years ago | 1004300 |
| 17. | DFA International Value I | 2 years ago | 992799 |
| 18. | American Funds American Mutual A | 2 years ago | 894545 |
| 19. | Capital Group American Mutual Comp | 2 years ago | 894545 |
| 20. | Janus Henderson Glb Life Scn I2 USD | 2 years ago | 866488 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Dodge & Cox | 2 years ago | 16264221 |
| 2. | PRIMECAP Management Company | 2 years ago | 14595152 |
| 3. | Morgan Stanley - Brokerage Accounts | 2 years ago | 6977833 |
| 4. | Dimensional Fund Advisors, Inc. | 2 years ago | 6273886 |
| 5. | Franklin Resources Inc | 2 years ago | 6211092 |
| 6. | Loomis, Sayles & Company LP | 2 years ago | 6066617 |
| 7. | Bank of America Corp | 2 years ago | 5197729 |
| 8. | Wellington Management Company LLP | 2 years ago | 4691916 |
| 9. | Charles Schwab Investment Management Inc | 2 years ago | 4383849 |
| 10. | Goldman Sachs Group Inc | 2 years ago | 2774357 |
| 11. | Cullen Capital Management, LLC | 2 years ago | 2714809 |
| 12. | Renaissance Technologies Corp | 2 years ago | 2636845 |
| 13. | Principal Financial Group Inc | 2 years ago | 2539265 |
| 14. | HHG PLC | 2 years ago | 2532937 |
| 15. | Northern Trust Corp | 2 years ago | 2167357 |
| 16. | Wells Fargo & Co | 2 years ago | 2009179 |
| 17. | UBS Group AG | 2 years ago | 1856657 |
| 18. | Grantham, Mayo, Van Otterloo & Co., LLC | 2 years ago | 1827263 |
| 19. | State Street Corporation | 2 years ago | 1756514 |
| 20. | BlackRock Inc | 2 years ago | 1723936 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...